PDCD1 and neoplasm: The results of flow cytometry showed that the quantity of tumor-infiltrating lymphocytes, CD3+ T cells and CD8+ T cells were significantly increased in Y332D plus anti-PD-1 therapy group (Additional file 1: Fig. S4a, b) (Fig. 7b, h).